New Human Technopole Strategic Plan 2024-2028 now online!
15 May 2024
New Human Technopole Strategic Plan 2024-2028 now online!
Five years since its inception, Human Technopole is now a dynamic institute where researchers from around the world have laid the foundations for unravelling the fundamental mechanisms of life across multiple biological scales – molecules, cells, tissues, organs, organisms, populations – in space and time.
Over the next few years Human Technopole will aim to consolidate the achieved results and continue pursuing its mission to improve human life and technology by focusing on four main objectives:
1) to foster fundamental cutting-edge research on human biology and human health;
2) to provide shared infrastructures, the National Facilities, to the national scientific community;
4) to enable the exploitation of research and technological innovation results via technology transfer.
The National Facilities in particular represent an important innovation promoted by our founding Ministries to support Italy’s scientific research through cutting edge technologies which, for the first time, will be made available to researchers throughout the country.
Meet Paolo Swuec, responsible for running the Italy’s first Cryo-EM Facility and, today, Head of the National Facility for Structural Biology at Human Technopole: a hub for cutting-edge research, facilitating the structural characterization of biological entities, ranging from tissues to amino acid side-chains.
The Glastonbury Group is among the recipients of the Data Insights Cycle 3 awards. The aim of the grant is to develop a machine learning model that identifies disease-relevant cell subpopulations whilst predicting a phenotype/disease of interest from large-scale single-cell RNA-seq data.
In collaboration with an international team of scientists, HT researchers identified a missense mutation in a gene involved in brain-intrinsic immunity as the genetic cause of SARS-CoV-2 brainstem encephalitis.
A study by Human Technopole, the Institute of Cancer Research and the Royal Marsden NHS Foundation Trust in London has shown that in prostate cancer the presence in the same tumour of cells with large differences in shape and genetic composition indicates an increased risk of relapse, including after a decade. The study may help doctors better tailor treatment for this disease, adopting more aggressive therapies in cases where these parameters indicate a higher risk of disease recurrence.
Meet Giovanni Fagà, Head of the National Facility for Genome Engineering & Disease Modelling. The core mission of the National Facility for Genome Engineering and Disease Modelling is to provide access to cutting-edge technologies in pluripotent stem cells, cell model generation, and genomic engineering.
Manage Cookie Consent
This website uses technical cookies to provide you with a better browsing experience and, subject to your consent, profiling cookies to offer you information and advertising in line with your preferences. For more details, you can consult our cookie policy by clicking on the link below, or set your preferences by clicking "set preferences". By selecting "accept cookies" you consent to the use of all types of cookies while you can revoke your consent by clicking on "refuse". By deciding to refuse or closing the banner, only the technical cookies necessary for the correct functioning of the site will be activated.
Technical cookies (required)
Always active
The technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.
Preferences
The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.
Third party cookies for statistics
The technical storage or access that is used exclusively for statistical purposes.The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.
Third party cookies for profiling
The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes.